Deucravacitinib in the treatment of psoriasis

Figures & data

Table 1. Efficacy results at week 12 of deucravacitinib against placebo, in a phase 2 clinical trial with moderate-to-severe psoriasis patients.

Endpoint	Deucravacitinib					Placebo (N = 45)
	3 mg every other day (N = 44)	3 mg daily (N = 44)	3 mg twice daily (N = 45)	6 mg twice daily (N = 45)	12 mg daily (N = 44)
PASI 75	9%	39%	69%	67%	75%	7%
PASI 90	7%	16%	44%	44%	43%	2%
PASI 100	2%	0%	9%	18%	25%	0%
sPGA 0/1	20%	39%	76%	64%	75%	7%
DLQI 0/1	16%	16%	42%	60%	64%	4%

PASI 75–75% or greater reduction from baseline in PASI score (primary endpoint). PASI 90–90% or greater reduction from baseline in PASI score. PASI 100–100% reduction from baseline in PASI score. sPGA 0/1 – static Physician’s Global Assessment score of 0 or 1 (clear or almost clear). DLQI 0/1 – Dermatology Life Quality Index score of 0 or 1 (no effect on the quality of life).

Table 2. Efficacy results at week 16 of deucravacitinib against placebo and an active comparator (apremilast), in two phase 3 clinical trial with moderate-to-severe psoriasis patients.

	Endpoint	Clinical trial	Deucravacitinib 6 mg once daily	Apremilast 30 mg twice daily	Placebo
Coprimary endpoints	PASI 75	POETYK PSO-1	58.7%	35.1%	12.7%
		POETYK PSO-2	53.6%	40.2%	9.4%
	sPGA 0/1	POETYK PSO-1	53.6%	32.1%	7.2%
		POETYK PSO-2	50.3%	34.3%	8.6%
Secondary endpoints	DLQI 0/1	POETYK PSO-1	40.7%	28.6%	10.6%
		POETYK PSO-2	38.0%	23.1%	9.8%
	ss-PGA 0/1	POETYK PSO-1	70.8%	39.1%	17.4%
		POETYK PSO-2	60.3%	37.3%	17.3%

PASI 75–75% or greater reduction from baseline in PASI score. sPGA 0/1 – static Physician’s Global Assessment score of 0 or 1 (clear or almost clear). DLQI 0/1 – Dermatology Life Quality Index score of 0 or 1 (no effect on the quality of life). ss-PGA 0/1 – scalp-specific Physician’s Global Assessment score of 0 or 1 (clear or almost clear).